How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comuPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Description:
The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in patients with metastatic castration-resistant prostate cancer (mCRPC)
Sponsor:
Rigshospitalet
Phase:
Phase 2
Contacts:
Marie Fosboel, MD (PRINCIPAL_INVESTIGATOR)Government Study Link:
NCT02964988 - Click here to see study onClinicalTrials.gov
NOTA-AE105
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- uPAR
Ligand Class: Small Proteins and Antibody Fragments
Chelator: NOTA
Radium-223 dichloride
Isotope(s):
RADIUM-223
Radioisotope: Ra-223
Theranostic Role: Therapeutic Agent
T1/2 (Half-Life): 11.4 Days
Decay Mode: ALPHA, BETA, GAMMA
Energy: Alpha (95%) 5-7.5 MeV Beta (3.6%) 445-492 keV Gamma (1%) 82-402 keV
Range: In Tissue <100 micrometers
Decay Daughters: 4 alpha daughters: Rn219, Po211,215, Bi211
Status: FDA Approval: XOFIGO® (2013)
Target(s):
- No Explicit Target
Inclusion
- Approved to receive Radium-223 therapy
- * Metastatic castration resistant prostate cancer
- Written and oral consent
Exclusion
- * Lack of communication skills
- Severe claustrophobia
- If a participant exhibits allergic reaction i the IMP, the participant will be excluded from further participation in the study
- Other known malignant disease
- Known allergy towards IMP
Share your feedback
Help us improve your experience